VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Expanding Cancer Therapy Portfolio

VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data for its BiTAC-ADC technology platform, which the company says could improve precision in cancer treatment by restricting therapeutic activation to tumors. The data, released on June 19, 2026, show that BiTAC-ADCs can distinguish between breast cancer and healthy cells and achieve dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.

The findings validate the potential of the BiTAC-ADC platform, which complements VERAXA’s existing BiTAC-TCE technology. Together, these platforms give the company two differentiated approaches applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.

VERAXA Biotech, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), focuses on antibody-based therapeutics including bispecific T cell engagers and bispecific ADCs. The company’s pipeline is advancing toward clinical development.

The announcement is significant because BiTAC-ADCs aim to overcome a key challenge in cancer therapy: off-target toxicity. By using two separately delivered components that only become active in the tumor microenvironment, the platform could reduce side effects while maintaining efficacy. The 3D spheroid data suggest the approach can penetrate solid tumors, a common hurdle for conventional ADCs.

VERAXA’s dual platform strategy—combining BiTAC-TCE and BiTAC-ADC—positions the company to address multiple cancer types. The BIO convention meetings will be critical for securing partnerships to advance these technologies into clinical testing. Investors and analysts will watch for any partnership announcements that could validate the platform’s commercial potential.

Forward-looking statements in the release caution that actual results may differ due to risks and uncertainties, including those in the company’s SEC filings. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Expanding Cancer Therapy Portfolio.

The post VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Expanding Cancer Therapy Portfolio appeared first on citybuzz.